A Phase 2 Study of Ruxolitinib, an Oral JAK1 and JAK2 Inhibitor, in Patients With Advanced Polycythemia Vera Who Are Refractory or Intolerant to Hydroxyurea

作者：Verstovsek Srdan^*; Passamonti Francesco; Rambaldi Alessandro; Barosi Giovanni; Rosen Peter J; Rumi Elisa; Gattoni Elisabetta; Pieri Lisa; Guglielmelli Paola; Elena Chiara; He Shui; Contel Nancy; Mookerjee Bijoyesh; Sandor Victor; Cazzola Mario; Kantarjian Hagop M; Barbui Tiziano; Vannucchi Alessandro M

来源：Cancer, 2014, 120(4): 513-520.

DOI：10.1002/cncr.28441

• polycythemia vera
• myeloproliferative neoplasm
• ruxolitinib
• Janus kinase (JAK) inhibitor
• phase 2

BACKGROUNDPolycythemia vera (PV) is a myeloproliferative neoplasm associated with somatic gain-of-function mutations of Januskinase-2 (JAK2). Therapeutic options are limited in patients with advanced disease. Ruxolitinib, an oral JAK1/JAK2 inhibitor, is active in preclinical models of PV. The long-term efficacy and safety of ruxolitinib in patients with advanced PV who are refractory or intolerant to hydroxyurea were studied in a phase 2 trial.
METHODSResponse was assessed using modified European LeukemiaNet criteria, which included a reduction in hematocrit to <45% without phlebotomy, resolution of palpable splenomegaly, normalization of white blood cell and platelet counts, and reduction in PV-associated symptoms.
RESULTSThirty-four patients received ruxolitinib for a median of 152 weeks (range, 31 weeks-177 weeks) or 35.0 months (range, 7.1 months-40.7 months). Hematocrit <45% without phlebotomy was achieved in 97% of patients by week 24. Only 1 patient required a phlebotomy after week 4. Among patients with palpable splenomegaly at baseline, 44% and 63%, respectively, achieved nonpalpable spleen measurements at weeks 24 and 144. Clinically meaningful improvements in pruritus, night sweats, and bone pain were observed within 4 weeks of the initiation of therapy and maintained with continued treatment. Ruxolitinib treatment also reduced elevated levels of inflammatory cytokines and granulocyte activation. Thrombocytopenia and anemia were the most common adverse events. Thrombocytopenia ofgrade 3 or anemia ofgrade 3 (according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0) occurred in 3 patients each (9%) (1 patient had both) and were managed with dose modification.
CONCLUSIONSRuxolitinib was generally well tolerated and provided rapid and durable clinical benefits in patients with advanced PV who were refractory or intolerant to hydroxyurea. Cancer 2014;120:513-20.

• 出版日期2014-2-15